1-[(二甲基氨基)甲基]咪唑 | 23230-39-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-[(二甲基氨基)甲基]咪唑
• 英文名称: 1-((N,N-dimethylamino)methyl)imidazole
• 英文别名: 1-[(dimethylamino)methyl]-imidazole；1-(1H-Imidazol-1-yl)-N,N-dimethylmethanamine；1-imidazol-1-yl-N,N-dimethylmethanamine
• CAS: 23230-39-9
• 化学式: C₆H₁₁N₃
• 分子量: 125.173
• InChiKey: VANQIHUBDZAOOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1-[(二甲基氨基)甲基]咪唑 在 正丁基锂 、 重水 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  N-二烷基氨基甲基取代的杂环的轻松合成

  摘要：

  亚胺离子是通过用琥珀酸酐处理缩醛胺而产生的。这些亚胺离子被杂环捕获，得到相应的N-二烷基氨基-甲基取代的杂环，这些杂环可通过碱水洗涤容易地从琥珀酸单酰胺副产物中分离出来。以高收率和高纯度获得杂环产物，而无需重结晶或蒸馏。

  DOI：

  10.1021/jo061723p
• 作为产物：
  描述：

  咪唑 、 四甲基甲烷二胺 在 丁二酸酐 、 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以75%的产率得到1-[(二甲基氨基)甲基]咪唑
  参考文献：
  名称：

  N-二烷基氨基甲基取代的杂环的轻松合成

  摘要：

  亚胺离子是通过用琥珀酸酐处理缩醛胺而产生的。这些亚胺离子被杂环捕获，得到相应的N-二烷基氨基-甲基取代的杂环，这些杂环可通过碱水洗涤容易地从琥珀酸单酰胺副产物中分离出来。以高收率和高纯度获得杂环产物，而无需重结晶或蒸馏。

  DOI：

  10.1021/jo061723p

文献信息

• 2-carbonyl substituted-5-hydroxy-1, 3-pyrimidines as antiinflammatory
  申请人：Warner-Lambert Company

  公开号：US05187175A1

  公开（公告）日：1993-02-16

  The present invention is novel compounds which are 2-carbonyl substituted-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.

  本发明为新颖的化合物，其为2-酮基取代的5-羟基-1,3-嘧啶及其可药用的酸加成盐或碱盐，以及用于其中的药物组合物和使用方法。发明的化合物现在发现具有作为5-脂氧合酶和/或环氧合酶抑制剂的活性，提供治疗有益于此类抑制的条件，包括炎症、关节炎、疼痛、发热等等。因此，本发明还涉及用于治疗所述条件的药物组合物或制造药物组合物的方法。
• 5-(1-(imidazol)methyl)-3,3-disubstituted-2(3H)furanone derivatives
  申请人：Marion Merrell Dow Inc.

  公开号：US05039691A1

  公开（公告）日：1991-08-13

  Furanone compounds and compositions having anticholinergic activity are described. The compounds have the formula: ##STR1## wherein: the dashed line indicates either the 4,5-unsaturated or the 4,5-dihydrofuranone ring; R.sub.1 and R.sub.2 may be the same or different and are hydrogen, thienyl, furanyl, or cycloalkyl (C.sub.3 -C.sub.6), benzyl, phenyl, substituted phenyl or substituted benzyl wherein the phenyl or benzyl group may be substituted with halogen, trifluoromethyl, lower alkyl, lower alkoxy or hydroxy; R.sub.3, R.sub.4 and R.sub.5 may be the same or different and are hydrogen, lower alkyl, lower alkyl substituted with a halogen, alkoxy, amino or carboxylic acid group, an alkyl or alkylene bridge between R.sub.4 and R.sub.5 or R.sub.3 and the ring N, trifluoromethyl, nitro, a cycloalkyl group containing 3 to 6 carbons, halogen, benzyl, phenyl, substituted phenyl or substituted benzyl, for which the substituents are the same as those set forth for R.sub.1 and R.sub.2 substituted benzyl or phenyl. R.sub.6 in the dihydrofuranone series is hydrogen or lower alkyl. Also described are the pharmaceutically acceptable quaternary alkyl and acid addition salts of such compounds. The compounds are particularly useful in the treatment of neurogenic bladder disorder and chronic obstructive pulmonary diseases.

  描述了具有抗胆碱作用的呋喃酮化合物和组合物。这些化合物的化学式为：##STR1##其中：虚线表示4,5-不饱和或4,5-二氢呋喃酮环；R.sub.1和R.sub.2可以相同也可以不同，可以是氢、噻吩基、呋喃基、环丙烷基（C.sub.3 -C.sub.6）、苄基、苯基、取代苯基或取代苄基，其中苯基或苄基可能被卤素、三氟甲基、低烷基、低烷氧基或羟基取代；R.sub.3、R.sub.4和R.sub.5可以相同也可以不同，可以是氢、低烷基、带有卤素、烷氧基、氨基或羧酸基的取代低烷基，R.sub.4和R.sub.5之间或R.sub.3和环N之间的烷基或烷基烯桥，三氟甲基、硝基、含有3至6个碳原子的环丙烷基、卤素、苄基、苯基、取代苯基或取代苄基，其取代基与R.sub.1和R.sub.2中所述的相同，取代苄基或苯基。二氢呋喃酮系列中的R.sub.6是氢或低烷基。还描述了这些化合物的药用可接受的季铵烷基和酸盐。这些化合物在治疗神经源性膀胱障碍和慢性阻塞性肺疾病方面特别有用。
• 1N-alkyl-n-arylpyrimidinamines and derivatives thereof
  申请人：DuPont Pharmaceuticals Company

  公开号：US06342503B1

  公开（公告）日：2002-01-29

  The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R4, R5, Z, Y, V, X, X′, J, K, L, and M are as defined herein.

  本发明提供了新颖的化合物、该化合物及其药物组合物，以及在治疗情感障碍、焦虑、抑郁、创伤后应激障碍、进食障碍、上核性麻痹、肠易激综合征、免疫抑制、阿尔茨海默病、胃肠疾病、厌食症、药物和酒精戒断症状、药物成瘾、炎症性疾病或生育问题中使用这些方法。本发明提供的新型化合物为以下公式的化合物： 其中R1、R3、R4、R5、Z、Y、V、X、X'、J、K、L和M如本文所定义。
• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION COMME MODULATEURS DES KINASES DÉPENDANTES DES CYCLINES
  申请人：NOVARTIS AG

  公开号：WO2010125402A1

  公开（公告）日：2010-11-04

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  该发明提供了式(I)的化合物及其盐、互变异构体、溶剂合物和N-氧化物；其中Q为CH或N；X为N、N+-O-或CR3；Y为N、N+-O-或CR3a；R1和R2分别选自氢和各种定义中的取代基；或R1和R2与它们连接的原子一起，形成一个可选择地取代的含氢碳环或杂环芳香或非芳香环，成员数为4到7；R3选自氢和各种取代基；R3a选自氢和各种定义中的取代基。还提供了含有式(I)的化合物的药物组合物，制备该化合物的方法以及该化合物的医药用途。式(I)的化合物具有作为CDK激酶抑制剂的活性，并可用于治疗癌症等增殖性疾病。
• Rational design, efficient syntheses and biological evaluation of N , N ′-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers
  作者：George Agelis、Amalia Resvani、Catherine Koukoulitsa、Tereza Tůmová、Jiřina Slaninová、Dimitra Kalavrizioti、Katerina Spyridaki、Antreas Afantitis、Georgia Melagraki、Athanasia Siafaka、Eleni Gkini、Grigorios Megariotis、Simona Golic Grdadolnik、Manthos G. Papadopoulos、Demetrios Vlahakos、Michael Maragoudakis、George Liapakis、Thomas Mavromoustakos、John Matsoukas

  DOI：10.1016/j.ejmech.2012.12.044

  日期：2013.4

  symmetrically bis-substituted imidazole analogs bearing at the N-1 and N-3 two biphenyl moieties ortho substituted either with tetrazole or carboxylate functional groups was designed based on docking studies and utilizing for the first time an extra hydrophobic binding cleft of AT1 receptor. The synthesized analogs were evaluated for their in vitro antagonistic activities (pA2 values) and binding affinities

  基于对接研究并首次利用AT1的额外疏水结合裂隙设计了一系列在N-1和N-3两个邻位被四唑或羧酸酯官能团邻位取代的对称双取代双咪唑类似物受体。评估了合成的类似物的体外拮抗活性（pA 2值）和与血管紧张素II AT1受体的结合亲和力（–logIC 50值）。其中，钾（编辑逻辑50  = 9.04）和钠（编辑逻辑50  = 8.54）的4-丁基-盐Ñ，Ñ双[2' - （2 ħ-四唑-5-基）联苯-4-基]甲基}溴化咪唑鎓（分别为12a和12b），其游离酸11（–logIC 50  = 9.46）和4-丁基-2-羟甲基-N，N'-双[[2'-（2 H-四唑-5-基）联苯-4-基]甲基}溴化咪唑鎓（14）（–logIC 50  = 8.37，pA 2  = 8.58）显示出对N AT1受体具有很高的拮抗活性（效力）。效力与氯沙坦相似或什至更高（–logIC 50  = 8.25，pA 2  = 8